Apocalypse or ripple? Ahead of first offers on price, new research predicts IRA impact on R&D will be modest
Ever since the Inflation Reduction Act was signed into law by President Joe Biden in August 2022, biopharma companies have leveled attacks on it, arguing the negotiations could be nothing more than glorified price setting that will reduce R&D spending.
But new research published Wednesday in Nature Biotechnology claims the IRA’s hit to overall industry revenue “will be modest,” and it “will not affect most top-selling drugs and will not likely result in large-scale defunding” of R&D.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.